Photo Credit: Freepik

The following is a summary of “Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy,” published in the April 2025 issue of European Journal of Neurology by Pasnoor et al. 

Researchers conducted a retrospective study to evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (GAMMAGARD LIQUID/Kiovig) in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) relapses during the ADVANCE-CIDP 1 trial.  

They included adult patients with confirmed CIDP relapse (≥ 1-point increase in adjusted inflammatory neuropathy cause and treatment (INCAT) disability scores from pre-treatment baseline) during ADVANCE-CIDP 1. Patients received an induction IVIG 10% dose (2 g/kg) followed by maintenance infusions at the same monthly equivalent dose of pre-randomization IVIG, 3-weekly for 6 months. The primary outcome was the responder rate (≥ 1-point decrease in adjusted INCAT scores at treatment cessation vs. pre-IVIG 10% baseline, in patients receiving placebo in ADVANCE-CIDP 1). Other outcomes included the responder rate across all patients relapsing on facilitated subcutaneous immunoglobulin (fSCIG) 10% or placebo in ADVANCE-CIDP 1, time to functional improvement (≥ 1-point decrease in adjusted INCAT score), and change in adjusted INCAT scores and rasch-built overall disability scale (R-ODS) centile scores from pre-IVIG 10% baseline. 

The results showed that 20 patients received IVIG 10% (4 in fSCIG 10%-relapse group, 16 in placebo-relapse group). The responder rate was 100.0% (95% CI: 80.6%–100.0%) in the placebo-relapse group and 95.0% (95% CI: 76.4%–99.1%) in the overall-relapse population. The median time for functional improvement was 25 days. At treatment cessation, mean changes from pre-IVIG 10% baseline in adjusted INCAT and R-ODS centile scores were −1.9 and 12.9, respectively. 

Investigators found that IVIG 10% effectively treated CIDP relapse and improved functional abilities. The treatment resulted in significant improvements in adjusted INCAT and R-ODS scores. 

Source: onlinelibrary.wiley.com/doi/full/10.1111/ene.70110